Status:
COMPLETED
Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Moderately to Severely Active Psoriatic Arthritis
Lead Sponsor:
Abbott
Conditions:
Arthritis
Psoriatic
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
Multicenter Study of the Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Moderately to Severely Active Psoriatic Arthritis
Eligibility Criteria
Inclusion
- Moderate to severe PsA
- Inadequate response to DMARD therapy
- Corticosteroid stable dose \<= 10 mg QD
- DMARDs must have been taken for 3 months and stable dose for 4 weeks
- MTX maximum dose = \<= 30 mg/week
- Active chronic plaque PS or documented history of chronic plaque PS
Exclusion
- No other active skin disease
Key Trial Info
Start Date :
March 1 2003
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
315 Patients enrolled
Trial Details
Trial ID
NCT00646386
Start Date
March 1 2003
Last Update
March 28 2008
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.